Literature DB >> 16078040

Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions.

Eva Ruiz1, Carmen Alemán, José Alegre, Jasone Monasterio, Rosa Ma Segura, Lluis Armadans, Ana Vázquez, Teresa Soriano, Tomás Fernández de Sevilla.   

Abstract

The angiogenesis system has been implicated in inflammatory and neoplastic processes; nevertheless, it has been little studied in relation to the pleural space. Our aim is to analyze pleural and plasma levels of the activators--vascular endothelial growth factor, basic fibroblastic growth factor, and inhibitors--endostatin and thrombospondin-1 and to estimate the association between these factors and related biochemical markers. We analyzed pleural fluid from 105 patients with one of the following types of pleural effusion: empyema or complicated parapneumonic, non-complicated parapneumonic, tuberculous, neoplastic and transudative. Angiogenesis activators were higher in exudates than in transudates (p < 0.001) and in empyema than in non-complicated parapneumonic patients (p < 0.001). Endostatin showed no significant differences. Trombospondin-1 showed higher levels in exudates than in transudates and in empyema than in non-complicated parapneumonic effusions (p < 0.001). In pleural exudates there was a positive correlation of angiogenesis activators and trombospondin-1 with low glucose and pH and high LDH. There was no correlation between pleural and plasma levels of the angiogenesis factors. We conclude that exudative pleural effusions showed higher vascular endothelial growth factor, basic-fibroblastic growth factor and trombospondin-1 values than transudative effusions that associated to low glucose and pH, and high LDH. There was no correlation between pleural and plasma concentrations, suggesting a compartmentalized response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078040     DOI: 10.1007/s00408-004-2533-0

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  40 in total

1.  Biomedicine. Clotting factors build blood vessels.

Authors:  P Carmeliet
Journal:  Science       Date:  2001-08-31       Impact factor: 47.728

Review 2.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 3.  Thrombospondin-1.

Authors:  J C Adams
Journal:  Int J Biochem Cell Biol       Date:  1997-06       Impact factor: 5.085

4.  Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.

Authors:  B K Zebrowski; S Yano; W Liu; R M Shaheen; D J Hicklin; J B Putnam; L M Ellis
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

5.  Vascular endothelial growth factor in pleural fluid.

Authors:  D Cheng; R M Rodriguez; E A Perkett; J Rogers; G Bienvenu; U Lappalainen; R W Light
Journal:  Chest       Date:  1999-09       Impact factor: 9.410

6.  Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis.

Authors:  L Strizzi; G Vianale; A Catalano; R Muraro; L Mutti; A Procopio
Journal:  Int J Oncol       Date:  2001-05       Impact factor: 5.650

Review 7.  Pathophysiology of pleural space infections.

Authors:  V B Antony; K A Mohammed
Journal:  Semin Respir Infect       Date:  1999-03

8.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Authors:  A Kraft; K Weindel; A Ochs; C Marth; J Zmija; P Schumacher; C Unger; D Marmé; G Gastl
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

9.  Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.

Authors:  K T Yeo; H H Wang; J A Nagy; T M Sioussat; S R Ledbetter; A J Hoogewerf; Y Zhou; E M Masse; D R Senger; H F Dvorak
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

10.  Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions.

Authors:  Enas A Hamed; Amira M El-Noweihi; Ashraf Z Mohamed; Azza Mahmoud
Journal:  Respirology       Date:  2004-03       Impact factor: 6.424

View more
  11 in total

1.  Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: A meta-analysis.

Authors:  Yong-Chun Shen; Meng-Qi Liu; Chun Wan; Lei Chen; Tao Wang; Fu-Qiang Wen
Journal:  Exp Ther Med       Date:  2012-03-14       Impact factor: 2.447

2.  Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis.

Authors:  Amene Saghazadeh; Nima Rezaei
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

3.  The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications.

Authors:  Foteini Economidou; George Margaritopoulos; Katerina M Antoniou; Nikolaos M Siafakas
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

4.  Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.

Authors:  Zhangqiang Xiang; Xiangyu Deng; Wenfeng He; Qian Yang; Laichao Ni; Marzieh Dehghan Shasaltaneh; Mazaher Maghsoudloo; Gang Yang; Jingbo Wu; Saber Imani; Qinglian Wen
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

5.  Diagnostic values of vascular endothelial growth factor and epidermal growth factor receptor for benign and malignant hydrothorax.

Authors:  Yan Gu; Min Zhang; Guo-Hua Li; Jun-Zhen Gao; Liping Guo; Xiao-Juan Qiao; Li-Hong Wang; Lan He; Mei-Ling Wang; Li Yan; Xiu-Hua Fu
Journal:  Chin Med J (Engl)       Date:  2015-02-05       Impact factor: 2.628

6.  Novel biomarker analysis of pleural effusion enhances differentiation of tuberculous from malignant pleural effusion.

Authors:  Kuan-Yuan Chen; Po-Hao Feng; Chih-Cheng Chang; Tzu-Tao Chen; Hsiao-Chi Chuang; Chun-Nin Lee; Chien-Ling Su; Lian-Yu Lin; Kang-Yun Lee
Journal:  Int J Gen Med       Date:  2016-06-11

7.  Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion.

Authors:  Dawei Chen; Xinyu Song; Fang Shi; Hui Zhu; Haiyong Wang; Nasha Zhang; Yan Zhang; Li Kong; Jinming Yu
Journal:  Oncotarget       Date:  2017-05-23

8.  Clinical characteristics and prognosis of serous body cavity effusions in patients with sepsis: a retrospective observational study.

Authors:  Ling-Yu Xing; Jun Yin; Mian Shao; Yi-Lin Yang; Ke-Yong Li; Ming-Ming Xue; Su-Cheng Mu; Zhan Sun; Ya-Ping Zhang; Chen-Ling Yao; Xun Chu; Chao-Yang Tong; Zhen-Ju Song
Journal:  BMC Anesthesiol       Date:  2018-11-14       Impact factor: 2.217

9.  Pleural tuberculosis: is radiological evidence of pulmonary-associated disease related to the exacerbation of the inflammatory response?

Authors:  Leila Antonangelo; Francisco S Vargas; Juliana Puka; Márcia Seiscento; Milena M P Acencio; Lisete R Teixeira; Ricardo M Terra; Roberta K B Sales
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

10.  Cytokines in pericardial effusion of patients with inflammatory pericardial disease.

Authors:  Konstantinos Karatolios; Rainer Moosdorf; Bernhard Maisch; Sabine Pankuweit
Journal:  Mediators Inflamm       Date:  2012-04-11       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.